MCID: PNC013
MIFTS: 46

Pancreatic Ductal Carcinoma malady

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Pancreatic Ductal Carcinoma

Aliases & Descriptions for Pancreatic Ductal Carcinoma:

Name: Pancreatic Ductal Carcinoma 12 14
Carcinoma, Pancreatic Ductal 42 69
Malignant Neoplasm of Duct of Wirsung 12
Carcinoma Pancreatic Ductal 52
Pancreatic Duct Cancer 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3587
ICD10 33 C25.3
ICD9CM 35 157.3
MeSH 42 D021441
SNOMED-CT 64 187793004 93939009

Summaries for Pancreatic Ductal Carcinoma

Disease Ontology : 12 A pancreatic carcinoma located in the pancreatic duct.

MalaCards based summary : Pancreatic Ductal Carcinoma, also known as carcinoma, pancreatic ductal, is related to adenosquamous pancreas carcinoma and pancreatitis. An important gene associated with Pancreatic Ductal Carcinoma is MUC6 (Mucin 6, Oligomeric Mucus/Gel-Forming), and among its related pathways/superpathways are Pathways in cancer and O-linked glycosylation. The drugs Paclitaxel and Irinotecan have been mentioned in the context of this disorder. Affiliated tissues include pancreas, endothelial and bone, and related phenotypes are cardiovascular system and cellular

Related Diseases for Pancreatic Ductal Carcinoma

Diseases related to Pancreatic Ductal Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 155)
id Related Disease Score Top Affiliating Genes
1 adenosquamous pancreas carcinoma 11.0
2 pancreatitis 10.7
3 motor neuron disease 10.3 MUC1 MUC6
4 laryngeal mucoepidermoid carcinoma 10.3 MUC1 MUC2
5 clitoris cancer 10.3 KRT20 MUC1
6 papilloma 10.3 MUC1 MUC6
7 ovarian squamous cell carcinoma 10.3 KRT20 MUC6
8 ascending colon cancer 10.3 KRT20 MUC2
9 cervix endometriosis 10.2 KRT20 MUC2
10 porokeratosis 10.2 MUC1 TP53
11 conjunctival cancer 10.2 MUC1 TP53
12 immunodeficiency due to a classical component pathway complement deficiency 10.2 CDKN2A MUC1
13 common variable immunodeficiency 10.2 TYMP VEGFA
14 bladder adenocarcinoma 10.2 CDKN2A MUC1
15 gestational ovarian choriocarcinoma 10.2 MUC1 MUC2 MUC6
16 urinary system disease 10.2 MUC1 MUC2 MUC6
17 acute gonococcal cystitis 10.2 TP53 VEGFA
18 small intestine leiomyoma 10.2 KRT20 TP53
19 fibular collateral ligament bursitis 10.2 MUC1 MUC2 MUC6
20 aortic aneurysm 10.2 CDKN2A VEGFA
21 clear cell hidradenoma 10.2 KRT20 TP53
22 spiradenoma 10.2 KRT20 TP53
23 refractory plasma cell neoplasm 10.2 MUC1 MUC2 MUC6
24 sarcomatoid mesothelioma 10.2 MUC1 MUC2 MUC6
25 brachydactyly, type b1 10.2 MUC1 MUC2 MUC6
26 vaginal villous adenoma 10.2 MUC1 MUC2 MUC6
27 spastic diplegia infantile type 10.2 MUC1 MUC2 MUC6
28 avian influenza 10.2 CDKN2A MUC1
29 breast pericanalicular fibroadenoma 10.2 KRT20 TP53
30 klatskin's tumor 10.2 KRT20 VEGFA
31 neurofibrosarcoma 10.2 KRT20 MUC1 MUC2
32 appendix mucinous cystadenocarcinoma 10.2 KRT20 MUC1 MUC2
33 angiolipomatosis, familial 10.2 KRT20 MUC1
34 episodic ataxia 10.2 CDKN2A MUC1
35 lung clear cell carcinoma 10.2 KRT20 MUC1 MUC2
36 clear cell adenofibroma 10.2 CDKN2A TP53
37 intestinal benign neoplasm 10.2 KRT20 MUC1 MUC2
38 lacrimal gland adenoid cystic carcinoma 10.2 CDKN2A TP53
39 pericardium leiomyoma 10.2 CDKN2A TP53
40 neuroretinitis 10.2 KRT20 MUC2 MUC6
41 acute stress disorder 10.2 KRT20 MUC2 MUC6
42 spondylarthropathy 10.2 CDKN2A TP53
43 odontotrichoungual-digital-palmar syndrome 10.2 KRT20 MUC1 MUC2
44 coronary stenosis 10.2 MUC1 TP53 VEGFA
45 polydactyly cleft lip palate psychomotor retardation 10.2 CDKN2A MUC1
46 lacrimal gland squamous cell carcinoma 10.1 CDKN2A TP53
47 human granulocytic anaplasmosis 10.1 MUC1 TP53 VEGFA
48 dental caries 10.1 MUC1 TP53 VEGFA
49 nasal cavity disease 10.1 MUC1 TP53 VEGFA
50 basophilic carcinoma 10.1 MUC1 MUC2 TP53

Graphical network of the top 20 diseases related to Pancreatic Ductal Carcinoma:



Diseases related to Pancreatic Ductal Carcinoma

Symptoms & Phenotypes for Pancreatic Ductal Carcinoma

MGI Mouse Phenotypes related to Pancreatic Ductal Carcinoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.8 TGM2 TP53 VEGFA CDKN2A MUC2 NUMB
2 cellular MP:0005384 9.76 TP53 TYMP VEGFA CDKN2A MUC2 NUMB
3 digestive/alimentary MP:0005381 9.43 TP53 VEGFA CDKN2A MUC2 NUMB SMAD4
4 neoplasm MP:0002006 9.1 TP53 VEGFA CDKN2A MUC2 SMAD4 TGM2

Drugs & Therapeutics for Pancreatic Ductal Carcinoma

Drugs for Pancreatic Ductal Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 137)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1,Early Phase 1 33069-62-4 36314
2
Irinotecan Approved, Investigational Phase 3,Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
3
Gemcitabine Approved Phase 3,Phase 2,Phase 1,Early Phase 1 95058-81-4 60750
4
Oxaliplatin Approved, Investigational Phase 3,Phase 2,Phase 1 61825-94-3 5310940 9887054 6857599, 9887054 43805
5
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1 154361-50-9 60953
6
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
7
Pancrelipase Approved Phase 3,Phase 2,Phase 1,Early Phase 1 53608-75-6
8
Axitinib Approved, Investigational Phase 3 319460-85-0 6450551
9
Hyaluronic acid Approved, Vet_approved Phase 3 9004-61-9 53477741 24759
10
Levoleucovorin Approved Phase 3,Phase 2,Phase 1 68538-85-2
11
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 54575, 6560146 143
12
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
13 pancreatin Phase 3,Phase 2,Phase 1,Early Phase 1
14
Erlotinib Hydrochloride Phase 3,Phase 2,Phase 1 183319-69-9 176871
15 topoisomerase I inhibitors Phase 3,Phase 2,Phase 1
16 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1,Early Phase 1
17 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
18 Trace Elements Phase 3,Phase 2
19 Vitamin B Complex Phase 3,Phase 2,Phase 1
20 Vitamins Phase 3,Phase 2
21 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Early Phase 1
22 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Early Phase 1
23 Protective Agents Phase 3,Phase 2
24 Antidotes Phase 3,Phase 2
25 Antimetabolites Phase 3,Phase 2,Phase 1,Early Phase 1
26 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Early Phase 1
27 Antimitotic Agents Phase 3,Phase 2,Phase 1,Early Phase 1
28 Micronutrients Phase 3,Phase 2
29 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1,Early Phase 1
30 Antiviral Agents Phase 3,Phase 2,Phase 1,Early Phase 1
31 Adjuvants, Immunologic Phase 3,Phase 1
32 Protein Kinase Inhibitors Phase 3,Phase 1,Phase 2
33 Liver Extracts Phase 3,Phase 1
34 acivicin Phase 3
35 Viscosupplements Phase 3
36 Hematinics Phase 3
37 Folate Nutraceutical Phase 3,Phase 2,Phase 1
38 Vitamin B9 Nutraceutical Phase 3,Phase 2,Phase 1
39
Cisplatin Approved Phase 1, Phase 2 15663-27-1 84093 441203 2767
40
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
41
Carboplatin Approved Phase 1, Phase 2 41575-94-4 10339178 498142 38904
42
Propofol Approved, Investigational, Vet_approved Phase 2,Phase 1 2078-54-8 4943
43
Rucaparib Approved, Investigational Phase 2 283173-50-2 9931954
44
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
45
Pemetrexed Approved, Investigational Phase 1, Phase 2 150399-23-8, 137281-23-3 446556 60843
46
Pembrolizumab Approved Phase 1, Phase 2 1374853-91-4
47
Bevacizumab Approved, Investigational Phase 1, Phase 2 216974-75-3
48
nivolumab Approved Phase 2,Phase 1 946414-94-4
49
Coal tar Approved Phase 1, Phase 2 8007-45-2
50
Metformin Approved Phase 2 657-24-9 14219 4091

Interventional clinical trials:

(show top 50) (show all 140)
id Name Status NCT ID Phase
1 Prevention of Upper Gastrointestinal Hemorrhage Using Albis® in the Patients of Locally Advanced Pancreatic Cancer Who Underwent Concurrent Chemoradiotherapy Not yet recruiting NCT02570529 Phase 4
2 Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer. Completed NCT00471146 Phase 3
3 An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation Completed NCT00132704 Phase 3
4 A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma Recruiting NCT02993731 Phase 3
5 A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenoca Recruiting NCT02715804 Phase 3
6 Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery Recruiting NCT01013649 Phase 3
7 Trial Comparing Adjuvant Chemotherapy With Gemcitabine Versus mFolfirinox to Treat Resected Pancreatic Adenocarcinoma Active, not recruiting NCT01526135 Phase 3
8 Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma Terminated NCT02101021 Phase 3
9 Efficacy Study of Gemcitabine, Paclitaxel, and Irradiation in the Treatment of Pancreatic Cancer Unknown status NCT00226746 Phase 2
10 Chemotherapy Selection Based on Therapeutic Targets for Advanced Pancreatic Cancer Unknown status NCT01394120 Phase 2
11 Modified FOLFIRINOX for Gemcitabine Refractory Pancreatic Cancer: A Phase II Multicenter Trial Unknown status NCT02440958 Phase 2
12 Nab-Paclitaxel+Cisplatin+Gemcitabine in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (PDA) Unknown status NCT01893801 Phase 1, Phase 2
13 Atu027 Plus Gemcitabine in Advanced or Metastatic Pancreatic Cancer (Atu027-I-02) Completed NCT01808638 Phase 1, Phase 2
14 Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer Completed NCT01580397 Phase 2
15 A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer Completed NCT00902291 Phase 2
16 A Study of AGS-1C4D4 in Pancreatic Cancer Subjects Previously Treated in Protocol 2008002 Completed NCT01608711 Phase 2
17 QUILT-3.019: Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer Completed NCT01040000 Phase 1, Phase 2
18 Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy Completed NCT01658943 Phase 2
19 A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation Completed NCT02042378 Phase 2
20 Capecitabine and Oxaliplatin in Patients With Advanced or Metastatic Pancreatic Adenocarcinoma Completed NCT00585078 Phase 2
21 Safety and Efficacy Evaluation of iAPA-DC/CTL Combined Gemcitabine Therapy on Advanced Pancreatic Cancer Recruiting NCT02529579 Phase 1, Phase 2
22 Parvovirus H-1 (ParvOryx) in Patients With Metastatic Inoperable Pancreatic Cancer Recruiting NCT02653313 Phase 1, Phase 2
23 Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors Recruiting NCT02810418 Phase 1, Phase 2
24 A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma Recruiting NCT02981342 Phase 2
25 Nab-pacliatxel Plus Gemcitabine in Korean Patients With Metastatic Pancreatic Ductal Adenocarcinoma Recruiting NCT02426281 Phase 2
26 Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma Recruiting NCT02754726 Phase 2
27 PEGPH20, Gemicitabine and Nab-Paclitaxel for Pancreatic Ductal Adenocarcinoma Recruiting NCT02487277 Phase 2
28 A Phase II Study of Neoadjuvant FOLFIRINOX Recruiting NCT02178709 Phase 2
29 Study of NAC of GA Therapy for Patients With BRPC Recruiting NCT02926183 Phase 2
30 Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers Recruiting NCT01631552 Phase 1, Phase 2
31 Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer Recruiting NCT02562898 Phase 1, Phase 2
32 Effect of Intratumoral Injection of Gene Therapy for Locally Advanced Pancreatic Cancer Recruiting NCT02806687 Phase 2
33 A Study of Epacadostat in Combination With a PD-1 Inhibitor and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207) Recruiting NCT03085914 Phase 1, Phase 2
34 Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates Recruiting NCT02723331 Phase 2
35 HIPEC as Neoadjuvant Treatment for Resectable Pancreatic Adenocarcinoma Recruiting NCT02850874 Phase 2
36 Near-infrared Image Guided Surgery in Pancreatic Adenocarcinoma Recruiting NCT02743975 Phase 1, Phase 2
37 Trial to Investigate Intensified Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer Recruiting NCT02125136 Phase 2
38 Neoadjuvant Plus Adjuvant or Only Adjuvant Nab- Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer Recruiting NCT02047513 Phase 2
39 Study of LOXO-101 (Larotrectinib) in Subjects With NTRK Fusion Positive Solid Tumors (NAVIGATE) Recruiting NCT02576431 Phase 2
40 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
41 Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma Active, not recruiting NCT02583477 Phase 1, Phase 2
42 Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma Active, not recruiting NCT02558894 Phase 2
43 PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Untreated Pancreatic Cancer Active, not recruiting NCT01839487 Phase 2
44 Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer Active, not recruiting NCT01280058 Phase 2
45 Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic Patients Active, not recruiting NCT02732938 Phase 2
46 Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma Active, not recruiting NCT02289898 Phase 2
47 Study of Tremelimumab in Patients With Advanced Solid Tumors Active, not recruiting NCT02527434 Phase 2
48 Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma Active, not recruiting NCT01431794 Phase 1, Phase 2
49 Phase 2 Evaluation of Multi-modality Algorithm for Non-metastatic Adenocarcinoma of Pancreas or Ampulla Active, not recruiting NCT02626520 Phase 2
50 The Effects of Neoadjuvant Metformin on Tumour Cell Proliferation and Tumour Progression in Pancreatic Ductal Adenocarcinoma Not yet recruiting NCT02978547 Phase 2

Search NIH Clinical Center for Pancreatic Ductal Carcinoma

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: carcinoma, pancreatic ductal

Genetic Tests for Pancreatic Ductal Carcinoma

Anatomical Context for Pancreatic Ductal Carcinoma

MalaCards organs/tissues related to Pancreatic Ductal Carcinoma:

39
Pancreas, Endothelial, Bone, Liver, Bone Marrow

The Foundational Model of Anatomy Ontology organs/tissues related to Pancreatic Ductal Carcinoma:

18
The Pancreatic Duct

Publications for Pancreatic Ductal Carcinoma

Articles related to Pancreatic Ductal Carcinoma:

(show top 50) (show all 78)
id Title Authors Year
1
The Clinical Significance of miR-34a in Pancreatic Ductal Carcinoma and Associated Molecular and Cellular Mechanisms. ( 27458977 )
2017
2
Insulin resistance is associated with the aggressiveness of pancreatic ductal carcinoma. ( 27552832 )
2016
3
Second primary pancreatic ductal carcinoma in the remnant pancreas after pancreatectomy for pancreatic ductal carcinoma: High cumulative incidence rates at 5 years after pancreatectomy. ( 27237099 )
2016
4
A case report on metastatic pancreatic tumor from pulmonary adenocarcinoma that difficult to differentiate from primary pancreatic ductal carcinoma. ( 27498937 )
2016
5
Efficacy of contrast-enhanced harmonic endoscopic ultrasonography in the diagnosis of pancreatic ductal carcinoma. ( 27184637 )
2016
6
Alternative splicing of NUMB, APP and VEGFA as the features of pancreatic ductal carcinoma. ( 26261495 )
2015
7
Clinicopathological Significance of ASC-Amino Acid Transporter 2 (ASCT2) Expression in Pancreatic Ductal Carcinoma. ( 24845232 )
2014
8
Alteration of strain ratio evaluated by transabdominal ultrasound elastography may predict the efficacy of preoperative chemoradiation performed for pancreatic ductal carcinoma: preliminary results. ( 24901166 )
2014
9
Successful management of metachronous liver metastasis after pancreaticoduodectomy for pancreatic ductal carcinoma using hepatectomy and chemotherapy: a case report. ( 24778053 )
2014
10
Pancreatic intraglandular metastasis predicts poorer outcome in postoperative patients with pancreatic ductal carcinoma. ( 23648465 )
2013
11
Increased expression of the large GTPase dynamin 2 potentiates metastatic migration and invasion of pancreatic ductal carcinoma. ( 21841817 )
2012
12
Epicatechin-rich cocoa polyphenol inhibits Kras-activated pancreatic ductal carcinoma cell growth in vitro and in a mouse model. ( 22190076 )
2012
13
Assessment of the interface between retroperitoneal fat infiltration of pancreatic ductal carcinoma and the major artery by multidetector-row computed tomography: surgical outcomes and correlation with histopathological extension. ( 22562451 )
2012
14
Clinicopathologic assessment of pancreatic ductal carcinoma located at the head of the pancreas, in relation to embryonic development. ( 22228049 )
2012
15
Nm23/nucleoside diphosphate kinase-A as a potent prognostic marker in invasive pancreatic ductal carcinoma identified by proteomic analysis of laser micro-dissected formalin-fixed paraffin-embedded tissue. ( 22892044 )
2012
16
Preoperative platelet-lymphocyte ratio in resected pancreatic ductal carcinoma: is it meaningful? ( 20579970 )
2012
17
Cytologic features of pancreatic intraepithelial neoplasia and pancreatitis: potential pitfalls in the diagnosis of pancreatic ductal carcinoma. ( 20730891 )
2011
18
Pancreatic cancer bears overexpression of neurotensin and neurotensin receptor subtype-1 and SR 48692 counteracts neurotensin induced cell proliferation in human pancreatic ductal carcinoma cell line PANC-1. ( 21272935 )
2011
19
Asymptomatic curable pancreatic ductal carcinoma detected during the follow-up of pancreatic cysts distinct from carcinoma. ( 26190721 )
2011
20
Expression of KL-6/MUC1 in pancreatic ductal carcinoma and its potential relationship with I^-catenin in tumor progression. ( 21466814 )
2011
21
KLF4 is a novel candidate tumor suppressor gene in pancreatic ductal carcinoma. ( 21224073 )
2011
22
Combination of MUC5ac and WT-1 immunohistochemistry is useful in distinguishing pancreatic ductal carcinoma from ovarian serous carcinoma in effusion cytology. ( 19856421 )
2010
23
Correlations between p53 gene mutations and histologic characteristics of pancreatic ductal carcinoma. ( 19248224 )
2009
24
Does contrast-enhanced ultrasound reveal tumor angiogenesis in pancreatic ductal carcinoma? A prospective study. ( 18845377 )
2009
25
Expression of EGF and EGFR strongly correlates with metastasis of pancreatic ductal carcinoma. ( 18505086 )
2008
26
Secretion of N-ERC/mesothelin and expression of C-ERC/mesothelin in human pancreatic ductal carcinoma. ( 19020717 )
2008
27
Expression of matrix metalloproteinase 9 in pancreatic ductal carcinoma is associated with tumor metastasis formation. ( 17378244 )
2007
28
Pancreatic ductal carcinoma: from the bench to the bedside. ( 16998251 )
2006
29
Reappraisal of the clinical significance of tumor size in patients with pancreatic ductal carcinoma. ( 17003643 )
2006
30
Strong prognostic value of nodal and bone marrow micro-involvement in patients with pancreatic ductal carcinoma receiving no adjuvant chemotherapy. ( 17072983 )
2006
31
Intercalated duct cell is starting point in development of pancreatic ductal carcinoma? ( 16018800 )
2005
32
Retroviral expression screening of oncogenes in pancreatic ductal carcinoma. ( 16125925 )
2005
33
Factors predicting recurrence after resection of pancreatic ductal carcinoma. ( 15968250 )
2005
34
Detection of tumor cell dissemination in pancreatic ductal carcinoma patients by CK 20 RT-PCR indicates poor survival. ( 16136352 )
2005
35
Evaluation of vascular signal in pancreatic ductal carcinoma using contrast enhanced ultrasonography: effect of systemic chemotherapy. ( 15951559 )
2005
36
Experimental trial for diagnosis of pancreatic ductal carcinoma based on gene expression profiles of pancreatic ductal cells. ( 16053509 )
2005
37
Alterations of tumor suppressor gene p16INK4a in pancreatic ductal carcinoma. ( 15985168 )
2005
38
Proteomic analysis of pancreatic ductal carcinoma cells after combined treatment with gemcitabine and trichostatin A. ( 16335935 )
2005
39
Terminally modified oligodeoxynucleotides directed against p53 in an orthotopic xenograft model: a novel adjuvant treatment strategy for pancreatic ductal carcinoma. ( 14707723 )
2004
40
Microarray-based gene expression profiling in pancreatic ductal carcinoma: status quo and perspectives. ( 14745573 )
2004
41
Gene expression profiling of microdissected pancreatic ductal carcinomas using high-density DNA microarrays. ( 15548371 )
2004
42
A comprehensive in vitro characterization of pancreatic ductal carcinoma cell line biological behavior and its correlation with the structural and genetic profile. ( 15258755 )
2004
43
Evaluation of blood flow in pancreatic ductal carcinoma using contrast-enhanced, wide-band Doppler ultrasonography: correlation with tumor characteristics and vascular endothelial growth factor. ( 15084983 )
2004
44
Role of the phosphatidylinositol 3'-kinase-Akt signal pathway in the proliferation of human pancreatic ductal carcinoma cell lines. ( 15084985 )
2004
45
Tumor stroma interactions induce chemoresistance in pancreatic ductal carcinoma cells involving increased secretion and paracrine effects of nitric oxide and interleukin-1beta. ( 14973050 )
2004
46
Proteomic profiling of pancreatic ductal carcinoma cell lines treated with trichostatin-A. ( 12783462 )
2003
47
Screening of genes specifically activated in the pancreatic juice ductal cells from the patients with pancreatic ductal carcinoma. ( 12824920 )
2003
48
Expressions of angiogenic factors in pancreatic ductal carcinoma: a correlative study with clinicopathologic parameters and patient survival. ( 12717266 )
2003
49
A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform. ( 12692724 )
2003
50
Proteomic analysis of pancreatic ductal carcinoma cells treated with 5-aza-2'-deoxycytidine. ( 14679576 )
2003

Variations for Pancreatic Ductal Carcinoma

Expression for Pancreatic Ductal Carcinoma

Search GEO for disease gene expression data for Pancreatic Ductal Carcinoma.

Pathways for Pancreatic Ductal Carcinoma

Pathways related to Pancreatic Ductal Carcinoma according to GeneCards Suite gene sharing:

(show all 18)
id Super pathways Score Top Affiliating Genes
1 12.37 CDKN2A SMAD4 TP53 VEGFA
2
Show member pathways
12.01 MUC1 MUC2 MUC6
3 11.95 SMAD4 TP53 VEGFA
4 11.89 SMAD4 TP53 VEGFA
5
Show member pathways
11.84 MUC1 MUC2 MUC6
6 11.69 CDKN2A SMAD4 TP53
7 11.67 MUC1 TP53 VEGFA
8
Show member pathways
11.62 MUC1 MUC2 MUC6
9 11.57 CDKN2A SMAD4 TP53
10
Show member pathways
11.4 CDKN2A SMAD4 TP53 VEGFA
11 11.23 CDKN2A TP53 VEGFA
12 11.19 CDKN2A SMAD4 TP53 VEGFA
13 11.14 SMAD4 TP53 VEGFA
14 11.08 CDKN2A TP53
15 10.89 CDKN2A TP53
16
Show member pathways
10.88 CDKN2A TP53
17 10.83 MUC2 SMAD4
18 10.79 CDKN2A TP53 TYMP VEGFA

GO Terms for Pancreatic Ductal Carcinoma

Cellular components related to Pancreatic Ductal Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 nuclear chromatin GO:0000790 9.13 MUC1 SMAD4 TP53
2 Golgi lumen GO:0005796 8.8 MUC1 MUC2 MUC6

Biological processes related to Pancreatic Ductal Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 in utero embryonic development GO:0001701 9.61 MUC1 SMAD4 VEGFA
2 response to hypoxia GO:0001666 9.58 MUC1 SMAD4 VEGFA
3 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.54 MUC1 MUC2 MUC6
4 negative regulation of cell growth GO:0030308 9.43 CDKN2A SMAD4 TP53
5 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.32 MUC1 TP53
6 maintenance of gastrointestinal epithelium GO:0030277 9.16 MUC2 MUC6
7 replicative senescence GO:0090399 8.96 CDKN2A TP53
8 O-glycan processing GO:0016266 8.8 MUC1 MUC2 MUC6

Sources for Pancreatic Ductal Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....